Synergistic Effects from Combination of Cryptotanshinone and Fosfomycin Against Fosfomycin-Susceptible and Fosfomycin-Resistant
Staphylococcus aureus
cryptanshinone
fosfomycin
synergistic effect
traditional Chinese medicine
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
03
2020
accepted:
09
07
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
Fosfomycin is now widely used to treat methicillin-resistant The MICs of fosfomycin and/or cryptanshinone were determined by agar dilution assay and checkerboard microdilution assay. Furthermore, synergistic effects from fosfomycin and/or cryptanshinone were analyzed by the time-kill assay in vitro. The combination of fosfomycin and cryptotanshinone had a synergistic effect on most (71.43%) of the FRSA and had a partial (28.57%) synergistic effect on a small part. In addition, time sterilization curve verified synergistic activity between cryptanshinone and fosfomycin against FSSA and FRSA, especially when fosfomycin was added for a second time. These data suggest that cryptanshinone combined with fosfomycin could be a novel treatment for FRSA and provide a new direction for the treatment of bacterial infections in the future.
Identifiants
pubmed: 32884307
doi: 10.2147/IDR.S255296
pii: 255296
pmc: PMC7431450
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2837-2844Informations de copyright
© 2020 Ruan et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cancer Prev Res (Phila). 2012 May;5(5):778-87
pubmed: 22490436
J Anat Physiol. 1882 Jul;16(Pt 4):526-67
pubmed: 17231444
J Clin Microbiol. 2012 Jun;50(6):1852-5
pubmed: 22442324
Biomed Res Int. 2016;2016:6413982
pubmed: 27366751
Bone Joint Res. 2017 Mar;6(3):132-136
pubmed: 28258116
J Biomed Biotechnol. 2009;2009:617509
pubmed: 19707532
Int J Antimicrob Agents. 2020 Jul;56(1):105985
pubmed: 32330585
J Clin Pharm Ther. 2018 Oct;43(5):614-625
pubmed: 30003555
J Glob Antimicrob Resist. 2018 Jun;13:264-265
pubmed: 29807203
Rev Esp Quimioter. 2003 Mar;16(1):15-40
pubmed: 12750755
Evid Based Complement Alternat Med. 2014;2014:450572
pubmed: 24782909
Zhonghua Yi Xue Za Zhi. 2018 Jan 16;98(3):181-185
pubmed: 29374911
Ann N Y Acad Sci. 1974 May 10;235(0):364-86
pubmed: 4605290
Anaesthesist. 2019 Oct;68(10):711-730
pubmed: 31555833
Res Vet Sci. 2014 Apr;96(2):251-3
pubmed: 24569298
J Am Chem Soc. 2003 Dec 24;125(51):15730-1
pubmed: 14677948
MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):220-224
pubmed: 30845116
Jpn J Antibiot. 1993 Feb;46(2):142-53
pubmed: 8331774
MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):214-219
pubmed: 30845118
Clin Microbiol Rev. 2016 Apr;29(2):321-47
pubmed: 26960938
Genome Biol. 2017 Jul 20;18(1):130
pubmed: 28724393
Int J Antimicrob Agents. 2010 Apr;35(4):333-7
pubmed: 20071153
Medicine (Baltimore). 2018 Aug;97(34):e11977
pubmed: 30142829
Infect Drug Resist. 2018 Nov 01;11:2107-2115
pubmed: 30464553
Microbiol Res. 2017 Jan;195:11-17
pubmed: 28024521
Science. 1969 Oct 3;166(3901):122-3
pubmed: 5809587
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28993329
Biochem J. 2013 Apr 1;451(1):69-79
pubmed: 23256780
Front Cell Infect Microbiol. 2018 Oct 03;8:348
pubmed: 30338245
Antibiotics (Basel). 2019 Aug 26;8(3):
pubmed: 31454985
Jpn J Infect Dis. 2018 Jul 24;71(4):312-314
pubmed: 29709971
Front Microbiol. 2016 Jan 11;6:1544
pubmed: 26793179
PLoS One. 2014 Dec 31;9(12):e113133
pubmed: 25551618
PLoS One. 2016 May 04;11(5):e0154829
pubmed: 27144405
FEMS Microbiol Lett. 1991 Nov 1;68(1):119-22
pubmed: 1769548